EVO Evotec SE IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1412558 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY2024*2024-12-31 | FY2023*2023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 796.97M | 781.43M |
| Cost of revenue | 682.09M | 606.38M |
| Gross profit | 114.88M | 175.05M |
| R&D expense | 50.86M | 68.53M |
| SG&A expense | 188.20M | 169.61M |
| Operating income | -142.52M | -47.51M |
| Pretax income | -193.98M | -80.59M |
| Income tax | 2.10M | 3.32M |
| Net income | -196.08M | -83.91M |
| EBITDA | -40.90M | 45.47M |
| EPS (basic) | -1.11 | -0.47 |
| EPS (diluted) | -1.11 | -0.47 |
| Balance sheet | ||
| Cash & equivalents | 306.39M | 510.91M |
| Short-term investments | 90.41M | 93.20M |
| Receivables | 116.32M | 98.40M |
| Inventory | 31.12M | 30.89M |
| Current assets | 681.96M | 903.16M |
| PP&E, netmay include right-of-use assets (IFRS) | 823.94M | 806.56M |
| Goodwill | 282.85M | 275.63M |
| Intangibles | 26.44M | 15.45M |
| Total assets | 1.91B | 2.25B |
| Current liabilities | 344.58M | 464.57M |
| Short-term debt | 27.11M | 129.97M |
| Total liabilities | 959.98M | 1.13B |
| Shareholders' equity | 952.52M | 1.12B |
| Shares outstanding | 177.55M | 177.19M |
| Cash flow statement | ||
| Operating cash flow | 18.22M | 36.44M |
| Capital expenditure | 117.47M | 213.32M |
| Free cash flow | -99.25M | -176.88M |
| Investing cash flow | -71.19M | -13.29M |
| Financing cash flow | -161.42M | 71.96M |
| Depreciation & amortization | 101.62M | 92.98M |
| Stock-based compensation | 5.04M | 9.63M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.